Home - Invivoscribe

Invivoscribe-Shop-Product-Availability-Key-1920×160-Image-2x-001

Invivoscribe-Shop-Product-Availability-Key-Image-2x-002

All Products

Cat #: 13080010
BCL1/JH Translocation Assay – Gel Detection
SUMMARY: Invivoscribe’s Gene Rearrangement and Translocation Assays represent a new approach to PCR-based clonality testing. These standardized ...
View Product
Cat #: 23080010
BCL1/JH Tube – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 23090020
BCL2/JH t(14;18) (mcr) Mix 2b – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 13090010
BCL2/JH t(14;18) Translocation Assay – Gel Detection
BACKGROUND: BCL2 translocations are reciprocal chromosome exchanges that place the bcl-2 proto-oncogene, located on chromosome 18, under aberrant tran...
View Product
Cat #: 13090020
BCL2/JH Translocation Assay – Gel Detection
SUMMARY: Invivoscribe’s Gene Rearrangement and Translocation Assays represent a new approach to PCR-based clonality testing. These standardized ...
View Product
Cat #: 23090050
BCL2/JH Tube A – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 23090060
BCL2/JH Tube B – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 23090070
BCL2/JH Tube C – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 14120010
FLT3 Mutation Assay – Gel Detection
BACKGROUND: Acute myeloid leukemia (AML) in general has a poor prognosis. Recent studies have described mutation of the FLT3 (fms-like tyrosine kinase...
View Product
Cat #: 14120020
FLT3 Mutation Assay MegaKit – Gel Detection
BACKGROUND: Acute myeloid leukemia (AML) in general has a poor prognosis. Recent studies have described mutation of the FLT3 (fms-like tyrosine kinase...
View Product
Cat #: 11000010
IGH + IGK B-Cell Clonality Assay – Gel Detection
SUMMARY: Invivoscribe’s Gene Rearrangement and Translocation Assays represent a new approach to PCR-based clonality testing. These standardized ...
View Product
Cat #: 21010060
IGH Framework 1 (FR1) – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 21010070
IGH Framework 2 (FR2) – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 21010080
IGH Framework 3 (FR3) – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 11010020
IGH Gene Clonality Assay – Gel Detection
SUMMARY: Invivoscribe’s Gene Rearrangement and Translocation Assays represent a new approach to PCR-based clonality testing. These standardized ...
View Product
Cat #: 11010040
IGH Gene Clonality Assay MegaKit – Gel Detection
SUMMARY: Invivoscribe’s Gene Rearrangement and Translocation Assays represent a new approach to PCR-based clonality testing. These standardized ...
View Product
Cat #: 11010010
IGH Gene Rearrangement Assay – Gel Detection
SUMMARY: Invivoscribe’s Gene Rearrangement Assays represent a new approach to PCR-based testing. These assays utilize a series of standardized m...
View Product
Cat #: 51010040
IGH Somatic Hypermutation Assay MegaKit v2.0 – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements are unique in length and sequence...
View Product
Cat #: 51010030
IGH Somatic Hypermutation Assay v2.0 – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements are unique in length and sequence...
View Product
Cat #: 21010010
IGH Tube A – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Territory

Detection

Regulatory Classification

Locus Target

Application

Product Type

Box Type

Design

Size

All Products

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020 Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Territory

Detection

Regulatory Classification

Locus Target

Application

Product Type

Box Type

Design

Size

All Products

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma